Introduction: Hepatocarcinoma constitutes one of the first five most frequent malignant neoplasms and the third in mortality, being responsible for nearly one million deaths yearly worldwide. In the majority of cases, i.e., 80%, they are diagnosed in advanced stages, with a very poor prognosis, with a survival rate of 8% at three years. Patients submitted to surgery present a recurrence of greater than 70% at five years. In Latin America, infection due to hepatitis C virus constitutes the main cause of hepatocarcinoma, and in Mexico, liver and bile-duct tumors represent the third cause of death by cancer, given the poor prognosis and despite the existing therapeutic schemas. Objective: This report concerns the use of Celecoxib in combination with Pentoxifylline in 3 patients with an advanced stage of hepatocarcinoma disease. Methods: The patients were diagnosed by means of biochemical, serologic, molecular, and imaging studies, in whom management was initiated and continued persistently with Pentoxifylline (400 mg/12 h, per os) plus Celecoxib (100 mg/12 h, per os) and vitamin supplements, clinical and laboratory studies were repeated at the time of cutting. Results: It is noteworthy that three patients present survival of longer than three years with reduction or slight modification of lesion size, as well as improvement in clinical, laboratory, and imaging stage. Conclusion: Although these results are encouraging; controlled studies will be conducted to confirm the efficacy of treatment showed here.